- Home
- CBUS vs IKNA Comparison
CBUS vs IKNA Comparison
Compare CBUS & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBUS
- IKNA
- Stock Information
- Founded
- CBUS 2010
- IKNA 2016
- Country
- CBUS United States
- IKNA United States
- Employees
- CBUS N/A
- IKNA N/A
- Industry
- CBUS Agricultural Chemicals
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- CBUS Industrials
- IKNA Health Care
- Exchange
- CBUS Nasdaq
- IKNA Nasdaq
- Market Cap
- CBUS 65.3M
- IKNA 63.7M
- IPO Year
- CBUS 2017
- IKNA 2021
- Fundamental
- Price
- CBUS $1.60
- IKNA $17.16
- Analyst Decision
- CBUS Strong Buy
- IKNA Buy
- Analyst Count
- CBUS 3
- IKNA 2
- Target Price
- CBUS $22.00
- IKNA $13.50
- AVG Volume (30 Days)
- CBUS 247.8K
- IKNA 434.6K
- Earning Date
- CBUS 08-07-2025
- IKNA 07-24-2025
- Dividend Yield
- CBUS N/A
- IKNA N/A
- EPS Growth
- CBUS N/A
- IKNA N/A
- EPS
- CBUS N/A
- IKNA N/A
- Revenue
- CBUS $4,751,000.00
- IKNA N/A
- Revenue This Year
- CBUS $31.23
- IKNA N/A
- Revenue Next Year
- CBUS $70.93
- IKNA N/A
- P/E Ratio
- CBUS N/A
- IKNA N/A
- Revenue Growth
- CBUS 104.78
- IKNA N/A
- 52 Week Low
- CBUS $1.38
- IKNA $0.97
- 52 Week High
- CBUS $10.76
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- CBUS 45.72
- IKNA 59.84
- Support Level
- CBUS $1.60
- IKNA $14.40
- Resistance Level
- CBUS $1.81
- IKNA $17.04
- Average True Range (ATR)
- CBUS 0.10
- IKNA 1.00
- MACD
- CBUS 0.02
- IKNA 0.05
- Stochastic Oscillator
- CBUS 27.59
- IKNA 82.26
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.